Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct. 28, 2011 - PRLog -- Global Data estimates that the global sarcopenia therapeutics market was valued at $10.1m in 2010. The market is forecasted to witness a consistent growth with a Compound Annual Growth Rate (CAGR) of 9.6% in the next eight years and it is expected to reach $20.9m in the year 2018. This is inclusive of the markets of the US, the UK, Italy and Japan. The growth in the market is primarily attributed to an increase in aging populations. The limited valuation of the market is primarily due to the fact that drug therapy is not recommended as the first line treatment for sarcopenia. At present, no drug has been approved for treating sarcopenia. The current competitive landscape consists of only generic and off-label drugs such as testosterone, estrogen and growth hormones. In countries such as Germany, Spain and France, no pharmacological treatment is being prescribed for treating sarcopenia so these countries were not included when estimating the global sarcopenia therapeutics market. The treatment landscape is not going to witness any major change in the future due to lack of promising drugs in the late stage pipeline. The global sarcopenia market is expected to remain as a low value market during the forecast period due to the domination of off-label drugs.

GlobalData’s analysis show thatno new molecule is expected to be launched until 2018 to cater to the need of the sarcopenia therapeutic market. Currently, the sarcopenia pipeline consist of only 5 molecules in various phases of development. Phase II and Phase I contribute 40% of the total pipeline with one molecule each, while 60% of the pipeline is contributed by preclinical development. This indicates that pharmaceutical companies are not focused on the research and development of new therapies for sarcopenia. The sarcopenia therapeutics pipeline is weak due to the unavailability of first-in-class molecules in the pipeline, although the unmet need of the sarcopenia therapeutic market is high and the treatment relies on older, non-pharmacological therapies and off label drugs. The market needs novel therapies offering better results in terms of safety and efficacy.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

At present, the sarcopenia theurapeutics are dominated by non-pharmacological therapies, particularly exercise and dietary supplements. The only available pharmacological treatment options are androgens such as testosterone and estrogen and growth hormones. The current competition in the sarcopenia therapeutic market is weak due to unavailability of effective treatment options with off label usage of generic drugs having low efficacy and safety profiles. The expected increase in old age populations increase the demand for therapy with better safety and efficacy profile. The introduction of new alternative therapies/non pharmacological therapies over the last few years is the main reason for the restrained growth of the market.

The sarcopenia therapeutics market has a high unmet need which has mainly arisen due to the lack of approved drugs for this disease. Therapies available for the treatments of sarcopenia have shown very low efficacy and safety profiles. In addition, available off label drugs provide only symptomatic relieve which leads to a high unmet clinical need in the sarcopenia therapeutic market. The market holds significant potential for novel entrants offering improved clinical outcomes to fulfill the high unmet need of the sarcopenia therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, “Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global sarcopenia therapeutics market. The report identifies the key trends shaping
and driving the global sarcopenia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global sarcopenia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Sarc...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.